We partner with biotech and pharmaceutical companies to advance novel cancer therapies through a comprehensive suite of services spanning preclinical research, regulatory strategy, clinical trial management, and specialty capabilities such as flow cytometry.

Founded in 2003 as a subsidiary of the Translational Genomics Research Institute (TGen), TD2 Oncology opened its doors on the Mayo Clinic campus in Scottsdale, Arizona. Our origins in translational science continue to shape our approach, blending deep oncology expertise with operational agility and scientific insight.

We support a wide range of therapeutic modalities and study types, including but not limited to radiopharmaceuticals, antibody-drug conjugates (ADCs), cell and gene therapies, and cancer vaccines. Our multidisciplinary team of scientists, clinicians, and regulatory experts is dedicated solely to oncology, bringing a deep understanding of cancer biology, trial complexity, and the evolving regulatory landscape. TD2 Oncology is expertly tailored to help sponsors navigate the unique challenges of cancer drug development. With focused expertise, personalized guidance, and a commitment to scientific excellence, we help sponsors overcome development hurdles and move their therapies forward with greater precision and speed.